What email address or phone number would you like to use to sign in to Docs.com?
If you already have an account that you use with Office or other Microsoft services, enter it here.
Or sign in with:
Signing in allows you to download and like content, and it provides the authors analytical data about your interactions with their content.
Embed code for: Poster plan (1)
Select a size
Medium chain acyl co-enzyme A dehydrogenase deficiency
Poster will consist of 5 sub-headings.
Clear white background
Visual colours will be associated with each sub-heading
Clear and Concise (no information overload)
Overview - opening, brief introduction to MCADD/ what?/ symptoms?/ Treatment?
Debate title - pros and cons.
Diagnosis and treatment - juvenile on-set/ assisted after care.
Prevention and awareness - this section will cover government schemes and the NHS screening programme. This section will also shed light on a geographical overview of MCADD on an international scale.
conclusion - End & refer to an incident that occurred in October 2010, “hospital neglect led to baby death” - telegraph
Points for introduction:
MCADD is a rare but treatable inherited disorder.
Disorder of fatty acid oxidation
Restricts the ability to breakdown medium chain fatty acids into acetyl CoA.
Acetyl-CoA - main function is to deliver the acetyl group to the citric acid cycle (Krebs cycle) to be oxidised for energy production.
Characterised by hypoglycaemia and sudden death.
problems occur because fat is only partially broken down, which leads to a lack of energy and a build-up of harmful substances in the body.
Medium-chain acyl-CoA dehydrogenase deficiency (MCADD) Testing started 2007, universal in England from 2009 Autosomal recessive.
Deficiency of Medium chain Acyl-CoA Dehydrogenase (needed to break down medium chain fatty acids) Complications arise during times of “ stress ” i.e. cannot break down fat stores so become hypoglycaemic leading to seizures/brain damage/death.
Generally no symptoms at birth, 1/3 rd remain asymptommatic Blood spot tests for raised Octanoylcarnitine Treatment = strict feeding regime .
Points for Debate:
Material created from other group members
Pros will located on the left column and Cons on the right column.
Fig 1 below will be situated between the two.
All points made in debate should correspond with leaflet and Poster.
The poster and leaflet must contain similar material but the poster will be more visual. Therefore the websites I have outlined above are my sources from where I have ascertained information regarding all the 5 sub-headings for the poster proposal.
The Poster and the debate should also go hand-in-hand, so therefore all pros and cons for the debate must be clearly visible on the poster. So general public can weigh the argument from their own perspective.
Finally it will be attached to a wall/whiteboard whilst we will be presenting, so we can refer to it from time to time.
Fact Column: (Located lower end of Poster)
1 in 10,000 babies in the UK has MCADD.
800,000 babies are born in the UK each year, and in 2010/2011 74 babies had a positive result for MCADD following newborn bloodspot screening.
Incidence is highest in the northern European population, mainly germany 1:4000
1 in 80 healthy people is a carrier of MCADD but will not have any symptoms.
If both parents are carriers, 1 in 4 chance for baby to be diagnosed with MCADD.
Images: *(enlargement may compromise image quality)*